Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

Gary Wittert, Evan Atlantis, Mathis Grossmann, Bu B. Yeap, Ann Conway, Bronwyn Stuckey, David Handelsman, Robert McLachlan, Carolyn Allan, Alicia Jenkins, Mark Daniel, Karen Bracken

    Research output: Contribution to journalMeeting Abstract

    Abstract

    Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.
    Original languageEnglish
    Pages (from-to)47-48
    Number of pages2
    JournalClinical Endocrinology
    Volume89
    Issue numberS1
    Publication statusPublished - Jun 2018

    Cite this

    Wittert, G., Atlantis, E., Grossmann, M., Yeap, B. B., Conway, A., Stuckey, B., ... Bracken, K. (2018). Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial. Clinical Endocrinology, 89(S1), 47-48.
    Wittert, Gary ; Atlantis, Evan ; Grossmann, Mathis ; Yeap, Bu B. ; Conway, Ann ; Stuckey, Bronwyn ; Handelsman, David ; McLachlan, Robert ; Allan, Carolyn ; Jenkins, Alicia ; Daniel, Mark ; Bracken, Karen. / Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial. In: Clinical Endocrinology. 2018 ; Vol. 89, No. S1. pp. 47-48.
    @article{2373be95ba694f059b9dc4b2506b04d4,
    title = "Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial",
    abstract = "Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers{\circledR}) as compared to lifestyle intervention alone, reduces T2D at 2 years.",
    author = "Gary Wittert and Evan Atlantis and Mathis Grossmann and Yeap, {Bu B.} and Ann Conway and Bronwyn Stuckey and David Handelsman and Robert McLachlan and Carolyn Allan and Alicia Jenkins and Mark Daniel and Karen Bracken",
    year = "2018",
    month = "6",
    language = "English",
    volume = "89",
    pages = "47--48",
    journal = "Clinical Endocrinology",
    issn = "0300-0664",
    publisher = "Wiley-Blackwell",
    number = "S1",

    }

    Wittert, G, Atlantis, E, Grossmann, M, Yeap, BB, Conway, A, Stuckey, B, Handelsman, D, McLachlan, R, Allan, C, Jenkins, A, Daniel, M & Bracken, K 2018, 'Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial', Clinical Endocrinology, vol. 89, no. S1, pp. 47-48.

    Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial. / Wittert, Gary; Atlantis, Evan; Grossmann, Mathis; Yeap, Bu B.; Conway, Ann; Stuckey, Bronwyn; Handelsman, David; McLachlan, Robert; Allan, Carolyn; Jenkins, Alicia; Daniel, Mark; Bracken, Karen.

    In: Clinical Endocrinology, Vol. 89, No. S1, 06.2018, p. 47-48.

    Research output: Contribution to journalMeeting Abstract

    TY - JOUR

    T1 - Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial

    AU - Wittert, Gary

    AU - Atlantis, Evan

    AU - Grossmann, Mathis

    AU - Yeap, Bu B.

    AU - Conway, Ann

    AU - Stuckey, Bronwyn

    AU - Handelsman, David

    AU - McLachlan, Robert

    AU - Allan, Carolyn

    AU - Jenkins, Alicia

    AU - Daniel, Mark

    AU - Bracken, Karen

    PY - 2018/6

    Y1 - 2018/6

    N2 - Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

    AB - Background: Low serum testosterone level is associated with in-creased risk of type 2 diabetes (T2D) in overweight men with im-paired glucose tolerance (IGT). It is not known whether testosterone (T) treatment is effective and safe for preventing T2D in this high- risk group.Aim: To determine in a large, multicentre, double- blinded placebo- controlled RCT, whether T treatment combined with lifestyle inter-vention (Weight Watchers®) as compared to lifestyle intervention alone, reduces T2D at 2 years.

    M3 - Meeting Abstract

    VL - 89

    SP - 47

    EP - 48

    JO - Clinical Endocrinology

    JF - Clinical Endocrinology

    SN - 0300-0664

    IS - S1

    ER -

    Wittert G, Atlantis E, Grossmann M, Yeap BB, Conway A, Stuckey B et al. Testosterone for type 2 diabetes prevention in men: A 2-year multicentre, randomised, double-blind, placebo-controlled trial. Clinical Endocrinology. 2018 Jun;89(S1):47-48.